Cancer drug by-product may be an untapped Parkinson's treatment

When combined with the original drug, the by-product produced a synergistic effect to inhibit prostate cancer cells.

When used alone, it reduced the buildup of a toxic protein in the brain associated with Parkinson’s disease.

Rucaparib, a drug used to treat ovarian, breast and prostate cancers, is broken down to its major metabolite, M324. CSIC Cell Chemical Biology M324 First M324 30% nine 20 the Spanish National Research Council Fe CSIC ighLightText__NxlGi">rucaparib M324 Rucaparib _NxlGi">rucaparib M324 M324 ">four rucaparib around 40%